PL2547679T3 - 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as ghrelin receptor antagonists or inverse agonists - Google Patents

2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as ghrelin receptor antagonists or inverse agonists

Info

Publication number: PL2547679T3
Authority: PL; Poland
Prior art keywords: diazaspiro; inden; dihydro; receptor antagonists; inverse agonists
Prior art date: 2010-03-19

Application number

PL11713083T

Other languages

Polish (pl)

Inventor

Samit Kumar Bhattacharya

Kimberly O'keefe Cameron

Dilinie Prasadhini Fernando

Daniel Wei-Shung Kung

Allyn Timothy Londregan

Kim Francis Mcclure

Suvi Tuula Marjukka Simila

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-19

Filing date

2011-03-11

Publication date

2016-02-29

2011-03-11 Application filed by Pfizer filed Critical Pfizer

2016-02-29 Publication of PL2547679T3 publication Critical patent/PL2547679T3/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL11713083T 2010-03-19 2011-03-11 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as ghrelin receptor antagonists or inverse agonists PL2547679T3 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US31552210P	2010-03-19	2010-03-19
US201161444401P	2011-02-18	2011-02-18
PCT/IB2011/051035 WO2011114271A1 (en)	2010-03-19	2011-03-11	2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
EP11713083.1A EP2547679B1 (en)	2010-03-19	2011-03-11	2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor

Publications (1)

Publication Number	Publication Date
PL2547679T3 true PL2547679T3 (en)	2016-02-29

Family

ID=44647714

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11713083T PL2547679T3 (en)	2010-03-19	2011-03-11	2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as ghrelin receptor antagonists or inverse agonists

Country Status (27)

Country	Link
US (2)	US8609680B2 (en)
EP (1)	EP2547679B1 (en)
JP (1)	JP5496409B2 (en)
KR (1)	KR101455917B1 (en)
CN (1)	CN102939290B (en)
AR (1)	AR080688A1 (en)
AU (1)	AU2011228699B2 (en)
BR (1)	BR112012023664B1 (en)
CA (1)	CA2792234C (en)
CY (1)	CY1118721T1 (en)
DK (1)	DK2547679T3 (en)
ES (1)	ES2557895T3 (en)
HK (1)	HK1182094A1 (en)
HR (1)	HRP20151232T1 (en)
HU (1)	HUE025774T2 (en)
IL (1)	IL221952A (en)
ME (1)	ME02330B (en)
MX (1)	MX2012010772A (en)
PH (1)	PH12012501800A1 (en)
PL (1)	PL2547679T3 (en)
PT (1)	PT2547679E (en)
RS (1)	RS54383B1 (en)
RU (1)	RU2524341C2 (en)
SG (1)	SG183812A1 (en)
SI (1)	SI2547679T1 (en)
TW (1)	TWI410423B (en)
WO (1)	WO2011114271A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101708989B1 (en) *	2012-06-04	2017-02-21	화이자 인코포레이티드	Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
EP2861566B1 (en) *	2012-06-13	2016-12-21	F. Hoffmann-La Roche AG	New diazaspirocycloalkane and azaspirocycloalkane
SI2900669T1 (en)	2012-09-25	2019-12-31	F. Hoffmann-La Roche Ag	Hexahydropyrrolo(3,4-c)pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (en)	2013-03-12	2015-09-16	Hoffmann La Roche	DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
RS56776B1 (en)	2013-11-26	2018-04-30	Hoffmann La Roche	Octahydro-cyclobuta [1,2-c;3,4-c']dipyrrole derivatives as autotaxin inhibitors
SI3119782T1 (en) *	2014-03-17	2018-06-29	reMYND NV Bio-Incubator	2,7-diazaspiro(3.5)nonane compounds
MX370659B (en)	2014-03-26	2019-12-19	Hoffmann La Roche	Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors.
CA2935612A1 (en)	2014-03-26	2015-10-01	F. Hoffmann-La Roche Ag	Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN104610143A (en) *	2015-02-12	2015-05-13	佛山市赛维斯医药科技有限公司	Glucokinase activator containing nitroquinoline structure and application of glucokinase activator
MA41898A (en)	2015-04-10	2018-02-13	Hoffmann La Roche	BICYCLIC QUINAZOLINONE DERIVATIVES
PE20180479A1 (en)	2015-09-04	2018-03-07	Hoffmann La Roche	NEW DERIVATIVES OF PHENOXYMETHYL
RU2724899C2 (en)	2015-09-24	2020-06-26	Ф. Хоффманн-Ля Рош Аг	New bicyclic compounds as dual inhibitors of atx/ca
MA42919A (en)	2015-09-24	2018-08-01	Hoffmann La Roche	BICYCLIC COMPOUNDS USED AS ATX INHIBITORS
CR20180143A (en)	2015-09-24	2018-05-03	Hoffmann La Roche	NEW BICYCLE COMPOUNDS AS DUAL INHIBITORS OF ATX / CA
KR20180054830A (en)	2015-09-24	2018-05-24	에프. 호프만-라 로슈 아게	Bifunctional compounds as autotaxine (ATX) inhibitors
KR20180096406A (en)	2017-02-21	2018-08-29	엘지전자 주식회사	refrigerator
CA3053329A1 (en)	2017-03-16	2018-09-20	F. Hoffmann-La Roche Ag	Heterocyclic compounds useful as dual atx/ca inhibitors
WO2018167113A1 (en)	2017-03-16	2018-09-20	F. Hoffmann-La Roche Ag	New bicyclic compounds as atx inhibitors
CN111225896B (en)	2017-07-28	2024-03-26	凯莫森特里克斯股份有限公司	Immunomodulatory compounds
CN108588215A (en) *	2018-05-03	2018-09-28	成都中创清科医学检验所有限公司	A kind of primer and its detection method for detecting the relevant SNP site of familial hypercholesterolemia neurological susceptibility
CN109970631A (en) *	2019-03-26	2019-07-05	上海吉奉生物科技有限公司	A kind of synthetic method of the iodo- 2- pyridylacetic acid of 5-
CN110256349B (en) *	2019-04-23	2020-09-08	苏州大学	Polysubstituted pyrazole and preparation method thereof
CN110172062B (en) *	2019-06-21	2022-01-07	南京药石科技股份有限公司	Synthesis method of monofluoro spiro compound and intermediate thereof
MX2023006186A (en)	2020-11-27	2023-08-07	Shenzhen Salubris Pharm Co Ltd	Benzimidazole derivative and preparation method therefor and medical use thereof.
US12186306B2 (en)	2020-12-10	2025-01-07	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
KR20220001745U (en)	2021-01-06	2022-07-13	성보라	Auxiliary cover for rear protection of automobile seat

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3595B (en)	1993-01-21	1995-12-27	Schering Corp	Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
NZ527364A (en)	2001-02-28	2004-12-24	Merck & Co Inc	Acylated piperidine derivatives as melanocortin-4 receptor agonists
CA2460340C (en)	2001-09-21	2011-02-15	Schering Corporation	Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
KR20040095239A (en)	2002-02-27	2004-11-12	화이자 프로덕츠 인코포레이티드	Acc inhibitors
SE0302811D0 (en)	2003-10-23	2003-10-23	Astrazeneca Ab	Novel compounds
AU2005247684B2 (en)	2004-05-12	2008-10-23	Pfizer Products Inc.	Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
UA84208C2 (en)	2004-05-25	2008-09-25	Пфайзер Продактс Инк.	Tetraazabenzo(e)azulene derivatives and analogs thereof
PA8660701A1 (en)	2005-02-04	2006-09-22	Pfizer Prod Inc	SMALL AGONISTS AND THEIR USES
GB0514018D0 (en) *	2005-07-07	2005-08-17	Ionix Pharmaceuticals Ltd	Chemical compounds
US8168783B2 (en)	2005-11-18	2012-05-01	Ono Pharmaceutical Co., Ltd.	Chemokine receptor antagonists and use thereof
EP1962835A2 (en)	2005-12-21	2008-09-03	Schering Corporation	Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
PT2463283E (en)	2006-04-20	2014-08-27	Pfizer Prod Inc	Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
JP2010503675A (en) *	2006-09-15	2010-02-04	シェーリングコーポレイション	Spiro-condensed azetidine derivatives useful for the treatment of pain, diabetes and disorders of lipid metabolism
CN101528227A (en) *	2006-09-15	2009-09-09	先灵公司	Azetidinone derivatives and methods of use thereof
JP2010511035A (en)	2006-11-29	2010-04-08	ファイザー・プロダクツ・インク	Spiroketone acetyl CoA carboxylase inhibitor
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
EP2297163B1 (en)	2008-05-28	2015-07-08	Pfizer Inc.	Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
WO2009144555A1 (en)	2008-05-28	2009-12-03	Pfizer Inc.	Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JPWO2009154132A1 (en) *	2008-06-19	2011-12-01	Ｍｓｄ株式会社	Spirodiamine-diarylketoxime derivatives
EP2318370A1 (en)	2008-07-29	2011-05-11	Pfizer Inc.	Fluorinated heteroaryls
KR101338540B1 (en)	2008-08-28	2013-12-06	화이자 인코포레이티드	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
TW201038580A (en)	2009-02-02	2010-11-01	Pfizer	4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
AP3179A (en)	2009-03-11	2015-03-31	Pfizer	Benzofuranyl derivatives used as glucokinase inhibitors
CA2754685A1 (en)	2009-03-11	2010-09-16	Pfizer Inc.	Substituted indazole amides
WO2010106457A2 (en)	2009-03-20	2010-09-23	Pfizer Inc.	3-oxa-7-azabicyclo[3.3.1]nonanes
TW201038572A (en) *	2009-03-25	2010-11-01	Gruenenthal Gmbh	Substituted spiro-amide compounds
US20120052130A1 (en)	2009-05-08	2012-03-01	Pfizer Inc.	Gpr 119 modulators
EP2427450A1 (en)	2009-05-08	2012-03-14	Pfizer Inc.	Gpr 119 modulators
NZ596467A (en)	2009-06-05	2014-01-31	Pfizer	L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
US20120083476A1 (en) *	2009-06-05	2012-04-05	Janssen Pharmaceutica Nv	Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2011005611A1 (en)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Neuromedin u receptor agonists and uses thereof

2011
- 2011-03-11 PL PL11713083T patent/PL2547679T3/en unknown
- 2011-03-11 PH PH1/2012/501800A patent/PH12012501800A1/en unknown
- 2011-03-11 MX MX2012010772A patent/MX2012010772A/en active IP Right Grant
- 2011-03-11 CA CA2792234A patent/CA2792234C/en not_active Expired - Fee Related
- 2011-03-11 AU AU2011228699A patent/AU2011228699B2/en not_active Ceased
- 2011-03-11 BR BR112012023664A patent/BR112012023664B1/en not_active IP Right Cessation
- 2011-03-11 CN CN201180014627.7A patent/CN102939290B/en not_active Expired - Fee Related
- 2011-03-11 SI SI201130664T patent/SI2547679T1/en unknown
- 2011-03-11 SG SG2012062667A patent/SG183812A1/en unknown
- 2011-03-11 EP EP11713083.1A patent/EP2547679B1/en active Active
- 2011-03-11 KR KR1020127027230A patent/KR101455917B1/en active IP Right Grant
- 2011-03-11 PT PT117130831T patent/PT2547679E/en unknown
- 2011-03-11 ME MEP-2015-189A patent/ME02330B/en unknown
- 2011-03-11 HU HUE11713083A patent/HUE025774T2/en unknown
- 2011-03-11 DK DK11713083.1T patent/DK2547679T3/en active
- 2011-03-11 RU RU2012137489/04A patent/RU2524341C2/en not_active IP Right Cessation
- 2011-03-11 JP JP2013500620A patent/JP5496409B2/en not_active Expired - Fee Related
- 2011-03-11 RS RS20150808A patent/RS54383B1/en unknown
- 2011-03-11 ES ES11713083.1T patent/ES2557895T3/en active Active
- 2011-03-11 WO PCT/IB2011/051035 patent/WO2011114271A1/en active Application Filing
- 2011-03-16 TW TW100109022A patent/TWI410423B/en not_active IP Right Cessation
- 2011-03-16 US US13/049,225 patent/US8609680B2/en active Active
- 2011-03-18 AR ARP110100888A patent/AR080688A1/en not_active Application Discontinuation
2012
- 2012-09-13 IL IL221952A patent/IL221952A/en not_active IP Right Cessation
2013
- 2013-08-08 HK HK13109302.9A patent/HK1182094A1/en not_active IP Right Cessation
- 2013-11-18 US US14/083,275 patent/US20140080756A1/en not_active Abandoned
2015
- 2015-11-16 HR HRP20151232TT patent/HRP20151232T1/en unknown
- 2015-12-04 CY CY20151101105T patent/CY1118721T1/en unknown

Also Published As

Publication number	Publication date
US8609680B2 (en)	2013-12-17
RU2012137489A (en)	2014-04-27
CN102939290B (en)	2015-09-16
MX2012010772A (en)	2012-11-06
WO2011114271A1 (en)	2011-09-22
EP2547679A1 (en)	2013-01-23
ES2557895T3 (en)	2016-01-29
IL221952A (en)	2016-02-29
AU2011228699A1 (en)	2012-09-20
RS54383B1 (en)	2016-04-28
EP2547679B1 (en)	2015-11-04
PT2547679E (en)	2016-01-27
CA2792234A1 (en)	2011-09-22
CN102939290A (en)	2013-02-20
TWI410423B (en)	2013-10-01
US20110230461A1 (en)	2011-09-22
HUE025774T2 (en)	2016-05-30
JP5496409B2 (en)	2014-05-21
KR20130001276A (en)	2013-01-03
AU2011228699B2 (en)	2016-05-19
CA2792234C (en)	2014-05-27
WO2011114271A8 (en)	2012-11-08
BR112012023664B1 (en)	2020-01-28
KR101455917B1 (en)	2014-11-03
US20140080756A1 (en)	2014-03-20
AR080688A1 (en)	2012-05-02
PH12012501800A1 (en)	2012-12-10
SG183812A1 (en)	2012-10-30
RU2524341C2 (en)	2014-07-27
TW201144312A (en)	2011-12-16
HRP20151232T1 (en)	2015-12-18
JP2013522354A (en)	2013-06-13
ME02330B (en)	2016-06-20
CY1118721T1 (en)	2017-07-12
SI2547679T1 (en)	2015-12-31
DK2547679T3 (en)	2016-01-11
BR112012023664A2 (en)	2016-08-16
HK1182094A1 (en)	2013-11-22

Publication	Publication Date	Title
PL2547679T3 (en)	2016-02-29	2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as ghrelin receptor antagonists or inverse agonists
BRPI1008060A2 (en)	2015-08-25	S1p5 receptor agonists and antagonists, and methods of use thereof.
HRP20150571T1 (en)	2015-07-03	SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
BRPI0817245A2 (en)	2015-06-16	Derivatives and quinoline as 5ht5a receptor antagonists
EP2344497A4 (en)	2012-05-30	Azaindole derivatives as crth2 receptor antagonists
IL210834A0 (en)	2011-04-28	Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
BRPI0809998A2 (en)	2014-10-14	IMIDAZO [1,2-A] PYRIDINE COMPOUND AS TYROSINE KINASE RECEPTOR INHIBITORS
IL205665A0 (en)	2010-11-30	Heteroaryl derivatives as orexin receptor antagonists
BRPI0911563A2 (en)	2016-07-12	progesterone antagonist use
IL200804A0 (en)	2010-05-17	Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
IL205608A0 (en)	2010-11-30	Triazole -substituted arylamide derivatives and their use as p2x3 and/or p2x2/3purinergic receptor antagonists
DK2401270T3 (en)	2014-01-13	Pyrazole derivatives used as CCR4 receptor antagonists.
IL209264A0 (en)	2011-01-31	Heteroaromatic monoamides as orexinin receptor antagonists
SI2238110T1 (en)	2012-02-29	5.6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors
IL201012A0 (en)	2010-05-17	Quinoline derivatives as crth2 receptor ligands
EP2125724A4 (en)	2012-02-15	Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists
IL241808B (en)	2018-04-30	N-(2,3-dihydro-1h-pyrrolo[2,3-b]jpyridin-5-yl)-4-quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
EP2262371A4 (en)	2012-05-09	Lpa receptor agonists and antagonists
HK1158640A1 (en)	2012-07-20	Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists 5-ht6 6-(1-)-
SMT201300020B (en)	2013-05-06	Isokinolinone derivatives as nk3 receptor antagonists
IL225299A0 (en)	2013-06-27	7-hydroxy- pyrazolo[1,5-a] pyrimidine compounds and their use as ccr2 receptor antagonists
BRPI1009257A2 (en)	2016-03-08	mineralocorticoid receptor antagonist and methods of use.
DK2287163T3 (en)	2014-11-03	2-AMINO-3-SULPHONYL-TETRAHYDRO-PYRAZOLO [1,5-A] PYRIDO-PYRIMIDINE ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PREPARATION AND USE thereof
IL200380A0 (en)	2010-04-29	Mineralcorticoid receptor antagonists for the treatment of endometriosis
LT3625221T (en)	2021-04-26	3-methyl-pyrrolidine-2,5-dione derivatives useful as cgrp receptor antagonists